Tag:
PricewaterhouseCoopers
Latest Headlines
Latest Headlines
Early VC rounds nosedive for biotech startups in Q1
After reporting last month that first-quarter venture investing in U.S. biotech dropped by 43%, PWC has drilled deeper into the numbers and noted that young life sciences outfits might have fared even worse than more mature startups.
Biotech VC deals, dollars shrivel in Q1 as devices see an upturn
Venture investing in biotech companies skidded 43% lower in the first quarter of the year compared with the strong numbers posted for the last three months of 2011.
Survey: Pharma lags peers in gaining trust via social media
Drugmakers have failed to gain the trust of most consumers on social networking sites, a new PricewaterhouseCoopers survey found.
From Union Square, everything at J.P. Morgan seems (relatively) fine
Okay, folks, I'll give it to you straight: This is my first J.P. Morgan Healthcare Conference. And it seems crazy busy for those here, as everyone networks in a frenzy only possible when so many
PwC finds mixed bag of VC trends as Q3 cash flow, deal count slows
The analysts at PricewaterhouseCoopers studied the most recent batch of quarterly data on life sciences venture investing--the lifeblood of the drug discovery industry--and came up with a mixed bag
PwC: Life Science VC funding dips in Q3 2011
The National Venture Capital Association and Pricewaterhouse Coopers say the biotech industry raised $1.1 billion in 96 deals in the third quarter of 2011, down 18% in dollars and 20% in the number
Flow of biotech venture dollars and deals shrivels in Q2
After you get past the bullish headline on PricewaterhouseCoopers' release on second quarter venture funding in the life sciences industry--up 37%!--you'll find that year-over-year the stream of
UPDATED: PwC tracks a spike in VC cash and deals for biotechs
PricewaterhouseCoopers and the National Venture Capital Association crunched the numbers on venture investing in the second quarter, tracking a 46% spike in the amount of venture cash being injected
For PwC, ops and business strengths drive PRTM buy
Drug process and regulatory expert PRTM will be acquired by global consultancy PricewaterhouseCoopers. PRTM will join the PwC global advisory practice, among the world's largest consultancies. PwC
PwC: FDA gets better grade for guidance, flunks review
PricewaterhouseCoopers took the drug development industry's temperature on its often turbulent relationship with the FDA and found it running high over some frequently mixed regulatory signals. But
